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The study of myeloma survival reported by Gahrton et al (2001) in
this issue of the British Journal of Cancer is both enlightening and
challenging to clinicians managing this condition. Awareness of
myeloma has been increased over the last few years as more
refined diagnostic criteria (Rajkumar et al, 2007), improved
investigational techniques (Ng et al, 2006) and better treatments
have become available. Myeloma incidence increases with age,
(Phekoo et al, 2004) but even allowing for an increasingly ageing
UK population there seems to be an increased incidence in
younger patients, the cause of which is unknown.
Myeloma is a heterogeneous disease clinically, phenotypically
and genetically. Some patients present with an indolent smoulder-
ing disease whereas in others it is rapidly progressive presenting
with painful bony lesions, fractures and hypercalcaemia, neuro-
logical damage, renal impairment and myelosuppression.
Improvements in supportive therapy, such as plasmapheresis,
bisphosphonates (Ashcroft et al, 2003) and vertebroplasty (Kose
et al, 2006), and antimicrobials for fungal and viral infections have
improved the quality of life for patients with myeloma.
Despite, advances in our understanding of the biology of
multiple myeloma, the disease remains incurable with conven-
tional treatment. Gahrton et al (2001) have shown that relative
survival, that is, the comparison of survival of individuals with the
disease relative to that of all individuals of the same age and sex in
the population from which they were drawn, has improved over
the period 1986–1999. The introduction of melphalan in the 1960s
(Speed et al, 1964) allowed for better disease control. With
chemotherapy, however, less than 5% of patients achieve a
complete remission (CR), median overall survival (OS) is 3–4
years and only 10–15% of patients survive more than 10 years,
with the disease inevitably relapsing and patients dying secondary
to disease progression and complications.
Although dose escalation and combination chemotherapy
improved response rates and disease-free interval in patients
younger than 65 years, it has failed to significantly impact on
survival in patients aged more than 65 years (Maclennan et al,
1992). Two recent population studies from Sweden (Kristinsson
et al, 2007) and SEERS in the United States (Brenner et al,
2008) have shown significantly improved 5- and 10-year survival,
but in both studies this improvement has been confined to those
under 60 years of age. Data related to patients diagnosed up to
2003 and 2004, respectively, suggesting that the improved survival
in those aged less than 60 years is because of the impact of
autologous stem cell transplantation, which is confined in the main
to those aged under 65–70 years. The impact of new agents
at presentation and relapse on long-term survival are yet to be
seen, these agents having only come into use after 2000. As the
efficacy seems to be similar in all age groups, similar improved
survival is to be expected in those more than 60 years of age in the
years to come.
Haematopoietic stem cell transplantation increases complete
response rates to 40% (Badros et al, 2002; Child et al, 2003) and
significantly prolongs progression-free survival but relapses
continue to occur with no plateau in the survival curves (Badros
et al, 2002). Overall, however, survival rates have been inconsistent
among studies. The IFM study (Attal et al, 1996) was the first to
demonstrate superiority of autologous stem cell transplantation
over conventional chemotherapy and the MRC Myeloma VII trial
(Child et al, 2003) later confirmed this, reporting OS rates of 52–
54 months. Another French study (Fermand et al, 1998) confirmed
the benefit for event-free survival (EFS) but not OS, whereas two
other studies (Blade et al, 2005; Barlogie et al, 2006) both showed
significantly increased CR rates but no prolongation in EFS or OS.
Differences in the design of the control treatment arms of these
studies may account for some of the discrepancies reported and
the benefits of autologous transplantation remain controversial
(Blade et al, 1996). Furthermore, the median age for transplanta-
tion in all major clinical trials is between 49 and 52 years, implying
that approximately 50% of patients are ineligible for this treatment
strategy. Similarly, tandem autologous transplantation increases
complete remission rates but has had a disappointing impact on
survival. Randomised trials of allogeneic stem cell transplantation
are lacking but registry data and small single centre studies suggest
this approach may induce prolonged disease-free survival in
selected individuals but at the cost of high treatment-related
mortality. This has fallen from 40 to 50% for patients reported to
the European Blood and Bone Marrow Transplant Register
between 1989 and 1991 to 30% for those transplanted between
1995 and 1999 (Gahrton et al, 1997). Registry data (Bjorkstrand
et al, 1996) shows a complete response rate at 5 years of 9% in
allogeneic transplantation and 4% in autografting. Maximum
duration of complete remission was 113 months for allogeneic vs
38 months for autologous transplantation with continuing late
relapses after CR up to 91 months in allogeneic patients and 38
months in autologous transplant patients. Non-myeloablative, *Correspondence: Dr S Schey; E-mail: steve.schey@kch.nhs.uk
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offers the opportunity of reduced mortality although retaining the
potential graft vs myeloma immunological effect. It has
extended the upper age for application of transplantation from
55 years for standard allogeneic transplantation to 70 years for
RIC transplantation (Peggs et al, 2002). The role of autologous
stem cell transplantation followed by a RIC allogeneic stem cell
transplant in newly diagnosed myeloma has recently been
compared with tandem autologous stem cell transplantation with
a significant improvement in EFS and OS for the RIC allograft arm
(35 vs 29 months, P¼0.02 and 80 vs 54 months, P¼0.01,
respectively) (Bruno et al, 2007). Once a patient relapses, there
is no consensus on the most suitable therapeutic regimen for
re-treatment and the next UKMF/NCRI MM X (Intensive) trial
is designed to investigate re-induction using a bortezomib
chemotherapy combination and to compare the benefit of
consolidation with a second stem cell transplant vs further
conventional chemotherapy.
As we have entered the new millennium, the poor results of
chemotherapy underscore the need for effective therapeutic
strategies to improve survival in multiple myeloma. Although the
aetiology of the condition remains unknown, the pathogenesis has
been intensively investigated, providing insight into the genetic
and molecular evolution of the disease and identifying a number of
new therapeutic targets (Mitsiades et al, 2007). The biological,
genetic and molecular variants of myeloma cells lead not only to
clinical diversity but also to differences in response to treatment.
The importance of cytokines (eg, interleukin IL-6, IL-1b, IL-10,
and tumour necrosis factor-a) and the role of cross talk between
myeloma cells and the bone marrow microenvironment in the
proliferation, apoptosis and migration of myeloma cells and
patient survival is becoming clearer (Chauhan et al, 1996; Gupta
et al, 2001). Small molecules designed to interrupt cellular
signalling pathways have led to the development of a variety of
new therapies (Corral et al, 1999). If these agents are to impact
significantly on myeloma survival, there is a need to investigate
their use, particularly in patients aged more than 65 years with
poor clinical and biological prognostic features (eg, del 13, t(4:14)
translocations and del 17p53) and in patients with renal failure
(Chanan-Khan et al, 2007). The outlook for relapsed disease has
been significantly improved in early trials using the new agents
bortezomib (Rajkumar et al, 2005) and the immunomodulatory
drugs (Richardson et al, 2002; Schey et al, 2004; Dimopoulos et al,
2005) both as a single agent and in combination with steroids and
chemotherapy agents. Trials will need to be designed to address
the optimal timing, scheduling and combinations of these agents
with conventional chemotherapy, to ensure that overall survival is
improved, in addition to improving quality of life by enhancing
progression-free survival. Another exciting area, yet to be fully
exploited, is the effect of the immune system in the minimal
residual disease setting and the role of the immunomodulatory
drugs may prove to be of particular interest in this situation.
(Davies et al, 2001; Dredge et al, 2002)
The widening differences in survival between socioeconomic
groups remain a concern. The improvements in survival in
patients aged 65 years and under, reported in 1990 and 2000 from
SEER and Europe, suggests that autologous stem cell transplanta-
tion has impacted significantly on survival over this period. The
high costs of haematopoietic stem cell transplantation from blood
or bone marrow presents a challenge for health care providers.
Data on 113827 patients from 580 centres in 35 European
countries between 1990 and 1999 (Gratwohl et al, 2002) suggested
that the increase in the number of patients receiving transplants
annually across Europe between 1990 and 1999 correlated with
economic factors. A further study from North America (Mitchell
et al, 1997) concluded that there was substantial variation in access
to bone marrow transplantation for black patients and that they
and those enroled in health maintenance organisations, those
covered by Medicaid, and self-pay patients were less likely to
receive a transplant. Myeloma is almost twice as common in the
African-Caribbean population and incidence increases signifi-
cantly with age. These two groups account for a large proportion of
socioeconomically deprived individuals in UK society. Patient
performance status and comorbidity plays a major role in patient
selection for transplantation and as comorbid problems, such as
chronic obstructive pulmonary disease and heart disease are more
frequently associated with low socioeconomic status and increas-
ing age; this may adversely impact on patient access to this form of
treatment, particularly in the 60–70 years age group.
There may, in addition, be other reasons why these groups have
restricted access to effective therapy. Some people may shun
conventional medical treatment for more traditional remedies,
only seeking medical help late in the course of their disease. Work
is needed to gain a better understanding of the cultural attitudes of
the African-Caribbean population towards cancer and its treat-
ment, and to target education and information using appropriate
channels. Elderly patients are less able or willing to travel to
receive treatment, either in specialised units or to access clinical
trials. Socioeconomically deprived groups may lack access to
information on the world-wide web, which could also be a factor in
limiting access to new, more effective treatments.
We are embarking on a new era in the treatment of myeloma
where the challenge for the next 10 years is to learn how to
maximise the therapeutic advantage of new agents that are rapidly
coming on line and translate the hope of the last 5 years into
improved outcomes for patients. This can only be done by
conducting well-designed clinical trials that are capable of
informing not just patients and clinicians of clinical outcomes,
but also healthcare planners, enabling them to allocate funding so
that the best treatments can be accessed by every patient.
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